Please upgrade your browser.
Prolonged exposure to tyrosine kinase inhibitors or early use of everolimus in metastatic renal cell carcinoma: are the two options alike?
We retrospectively analyzed metastatic renal cell carcinoma (RCC) patients treated with 3 targeted agents. Patients started the sequence with a tyrosine kinase inhibitor (TKI), sunitinib or sorafenib, and were divided into 2 groups based on the order in which they received the other reciprocal TKI and everolimus (EVE): TKI-TKI-EVE group (nÂ =Â 19) and TKI-EVE-TKI group (nÂ =Â 14).
Are you PatientSmart? Get in on the ground floor of something that has the potential to fundamentally transform medicine. Best of all, it's FREE! www.PatientSmart.org(SM).
Today, I list 4 biopharmas I feel offer strong upside potential in the short and medium term. With these catalysts quickly approaching, we can expect some nice shorter-term appreciation under normal market conditions. I feel the 4 stocks I list here are also strong speculation investments.
Results with personalized immunotherapy support phase III study, authors say...
Anyone who lived or worked at Camp Lejeune between 1957 and 1987 and have any of these conditions should contact the VA Hospital or the Wilson County Veteran's Service Office at 615-444-2460.
The incidence and consequences of positive surgical margins after partial nephrectomy are important issues in the management of localized renal cell carcinoma. A recent population-based study demonstrates a slightly higher rate of positive margins...
As we officially commemorate National Volunteer Week, I am giving a shout out to those 65 million family caregivers nationwide -- most of them caring for someone over age 50 -- who essentially have volunteered to care for a loved one who is sick, getting older, or has a disorder or disability. Caregivers are an invaluable volunteer army drafted into service to help loved ones remain at home rather than in facilities and institutions.
Aveo Pharmaceuticals' (AVEO) big day is getting closer - on May 2nd, the FDA's Oncologic Drugs Advisory Committee (ODAC) is scheduled to review the company's lead drug candidate tivozanib for the treatment of advanced renal cell carcinoma (RCC).
Adding "chemical shift" techniques to MRI can help differentiate clear cell renal cell carcinoma from other types of renal cell cancer, a new study shows. That differentiation can help physicians better determine treatment for these patients.
In the newly diagnosed patient, a multimodal approach optimizes survival and quality of life.
|Powered by NeonCRM|